Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

During the first half of this year, Ocrevus generated 1.04 billion Swiss francs – more than 90% of that was from use in the US. Roche’s MS drug Ocrevus earns blockbuster status a year after ...

Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and ...

Ocrevus is a medicine commonly used to treat primary progressive MS, but it can take up to four hours to receive intravenously. A new version called “Ocrevus Zunovo” was recently approved by ...

The FDA has approved three such drugs for MS. Ocrelizumab (Ocrevus) treats relapsing forms of MS, including: Clinically isolated syndrome Relapsing-remitting MS Active secondary progressive MS in ...

Ocrelizumab (Ocrevus), is a drug that sticks to B cells and destroys them. That helps prevent MS damage and symptoms. It’s approved by the FDA for: Clinically isolated syndrome Relapsing ...